Efficacy of Synthetic Bone Graft for Treatment of Peri-implantitis

NCT03213210 — Not applicable, Terminated, 5 participants, Sunstar Americas

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Clinical Efficacy of Easy-graft CLASSIC for the Treatment of Peri-implantitis

RegistryNCT03213210
StatusTerminated - Insufficient recruitment
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, treatment
Enrollment5 (Actual)
SponsorSunstar Americas (Industry)
ConditionsPeri-Implantitis
Interventionseasy-graft CLASSIC (beta-Tricalcium Phosphate) (Device)
Datesstart 2018-11-12, primary completion 2019-12-31, completion 2020-01-31, first posted 2017-07-11, last updated 2021-04-08
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
All trials for Peri-Implantitis All trials of easy-graft CLASSIC (beta-Tricalcium Phosphate)

-Summary

Single arm study to evaluate the effectiveness of treatment approach using a new moldable beta-tricalcium phosphate(TCP) bone graft material and polylactide membrane in peri-implantitis.

Expand all sections  ·  Collapse all

+Arms and interventions

ArmTypeInterventionsDescription
Device treatmentOtherDevice: easy-graft CLASSIC (beta-Tricalcium Phosphate)easy-graft CLASSIC (beta-Tricalcium Phosphate) grafting covered with polylactide membrane
  • easy-graft CLASSIC (beta-Tricalcium Phosphate) (Device), also known as GUIDOR Bioresorbable Matrix Barrier: easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.

+Outcome measures

Primary outcomes

  • Change in Probing Depth [Change from baseline at 12 months after the surgery]: Distance of probe penetration from gingival margin to bottom of peri-implant pocket
  • Esthetic Satisfaction [At 12 months after the surgery]: To be assessed by examiner and subject using the Visual Analog Scales

Secondary outcomes

  • Change of Marginal Bone Level [Change from baseline at 6 and 12 months after the surgery]: Change of marginal bone level on periapical standardized radiographs from baseline.
  • Change in Width of Keratinized Tissue [Change from baseline at 6 and 12 months after the surgery]: Distance between free gingival margin and mucogingival junction
  • Change in Clinical Attachment Level [Change from baseline to at 6 and 12 months after the surgery]: Distance of probe penetration from fixed reference to bottom of peri-implant

+Eligibility

Sex: All, ages: 21 Years to any

Inclusion Criteria:

* Subject has read and signed the Institutional Review Board approved consent form before treatment.
* Subject must be age 21 or above.
* Subject must be willing and able to follow study procedures and instructions.
* Subject affected by moderate to severe peri-implant disease.
* Treated chronic periodontitis and proper periodontal maintenance care.
* Dental implant must meet the following criteria to be selected for the study:

  1. Implant presenting Probing Depth ≥ 6 mm
  2. Radiographic implant bone loss more than 25% of the implant length (Apex of the implant to implant platform) .
  3. Peri implant bone defect being a buccal dehiscence and semicircular bone resorption to the middle of the implant body, buccal dehiscence and circular bone resorption with lingual bone plate intact or circular bone resorption with buccal and lingual bone plates intact
  4. Single tooth implant restoration or implant supported fixed partial denture.

Exclusion Criteria:

* Subjects participating (currently or within 30 days prior to enrollment) in other clinical trials involving therapeutic intervention (either medical or dental).
* Subjects with poor oral hygiene as indicated by a score of greater than 50% on the O'Leary Plaque Index.
* Subjects with a systemic condition, which would preclude periodontal treatment, including but not limited to uncontrolled diabetes.
* Subjects with acute infectious lesions in the areas intended for treatment.
* Subjects taking chronic (i.e., > 2 weeks), therapeutic doses of medications known to affect bone metabolism such as nonsteroidal anti-inflammatory drugs or bisphosphonates. Prophylactic aspirin (≤ 325 mg q.d.) for cardiovascular indications will be permitted in subjects.
* Female subjects who are pregnant or lactating, or sexually-active female subjects who are of childbearing potential and are not using hormonal or barrier methods of birth control. (except for when a result of pregnancy test is negative)
* Subjects who are on any chronic antibiotic or steroidal therapy.
* Smoker using more than 10 cigarettes or equivalent per day.
* Smoker using cigar, smokeless tobacco use or e-cigarette.
* Subjects diagnosed with drug induced gingival hyperplasia (e.g. calcium channel blockers).
* Subjects with radiographic evidence of pathology in other areas of the mouth besides implant area to be treated.
* Implant mobility.
* Subjects with parafunctional habits and not wearing bite guard.

+Posted results

Participant flow

MilestoneDevice Treatment
Started5
6-month follow-up3
Completed0
Not completed5

Outcome results

  • Change in Probing Depth (Primary)
  • Esthetic Satisfaction (Primary)
  • Change of Marginal Bone Level (Secondary), Mean, percentage of bone height change: Device Treatment 3.3 +/- 5.8
  • Change in Width of Keratinized Tissue (Secondary)
  • Change in Clinical Attachment Level (Secondary)

Adverse events

Time frame: 6 months after the surgery

ArmDeathsSerious adverse eventsOther adverse events
Device Treatment0/5 (0.0%)0/5 (0.0%)0/5 (0.0%)

+Locations (1)

FacilityCityCountryStatus
Creighton University School of DentistyOmaha, NebraskaUnited States

+Study documents